GlobeNewswire

Atico Reports on Union Negotiations at El Roble Mine, Colombia

Share

VANCOUVER, B.C., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Atico Mining Corporation (TSX.V: ATY | OTC: ATCMF) (“Atico” or “Company”) reports that it has received strike action notice from the local union after being unable to reach a new 2 year collective agreement at the El Roble mine.

The Company continues to negotiate with the local union and is working diligently towards bringing a swift and satisfactory resolution for all parties involved. Mining operations and exploration activity at El Roble have been suspended.

The Company has activated its protocol to maintain mine and infrastructure on stand by while the strike is ongoing and is prepared to reinitiate operations as soon as an agreement is reached.

El Roble Mine

The El Roble mine is a high grade, underground copper and gold mine with nominal processing plant capacity of 850 tonnes per day, located in the Department of Choco in Colombia. Its commercial product is a copper-gold concentrate.

Since obtaining control of the mine on November 22, 2013, Atico has upgraded the operation from a historical nominal capacity of 400 tonnes per day.

El Roble has Proven and Probable reserves of 1.47 million tonnes grading 3.40% copper and 1.88 g/t gold, at a cut-off grade of 1.93% copper equivalent. Mineralization is open at depth and along strike and the Company plans to further test the limits of the deposit.

On the larger land package, the Company has identified a prospective stratigraphic contact between volcanic rocks and black and grey pelagic sediments and cherts that has been traced by Atico geologists for ten kilometers. This contact has been determined to be an important control on VMS mineralization on which Atico has identified numerous target areas prospective for VMS type mineralization occurrence, which is the focus of the current surface drill program at El Roble.

About Atico Mining Corporation

Atico is a growth-oriented Company, focused on exploring, developing and mining copper and gold projects in Latin America. The Company operates the El Roble mine and is pursuing additional acquisition opportunities. For more information, please visit www.aticomining.com. 

ON BEHALF OF THE BOARD

Fernando E. Ganoza
CEO
Atico Mining Corporation

Trading symbols: TSX.V: ATY | OTC: ATCMF

Investor Relations
Igor Dutina
Tel: +1.604.633.9022

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ‘‘U.S. Securities Act’’), or any state securities laws, and may not be offered or sold in the United States, or to, or for the account or benefit of, a "U.S. person" (as defined in Regulation S of the U.S. Securities Act) unless pursuant to an exemption therefrom. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

Cautionary Note Regarding Forward Looking Statements

This announcement includes certain “forward-looking statements” within the meaning of Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation the use of net proceeds, are forward-looking statements. Forward- looking statements involve various risks and uncertainties and are based on certain factors and assumptions. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; uncertainty of estimates of capital and operating costs; the need to obtain additional financing to maintain its interest in and/or explore and develop the Company’s mineral projects; uncertainty of meeting anticipated program milestones for the Company’s mineral projects; and other risks and uncertainties disclosed under the heading “Risk Factors” in the prospectus of the Company dated March 2, 2012 filed with the Canadian securities regulatory authorities on the SEDAR website at www.sedar.com

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPress release

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED19.7.2019 12:00:00 CESTPress release

Rapala VMC Corporation Half year financial report July 19, 2019 at 1:00 p.m. RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED January-June (H1) in brief: Net sales were 141.2 MEUR, down 1% from previous year (142.5). With comparable exchange rates sales were 2% lower than last year. Operating profit was 11.4 MEUR (15.3), down 25%.1) Comparable operating profit* was 12.0 MEUR (15.2), down 21%. 1) Cash flow from operations was 11.5 MEUR (5.9). 2) Earnings per share was 0.17 EUR (0.23), down 26%. Full year guidance unchanged: Full year net sales with comparable FX rates expected to be around last year’s level and comparable operating profit* to increase from last year. Strong second half of the year expected: record strong order book in North America, improvements in Indonesian lure factory combined with rigorous management of fixed costs. Uncertainties and risks relate to US-China trade relations, global ec

Scientific Beta defends the role of the Size factor in multi-factor portfolios19.7.2019 11:32:00 CESTPress release

Scientific Beta defends the role of the Size factor in multi-factor portfolios Research shows that omitting the Size factor would be costly for investors New research from Scientific Beta, the smart beta index provider, has shown that the Size factor improves model fit, delivers a significant positive premium in the presence of other factors, and contributes positively to the performance of multi-factor portfolios. The Size effect is well established in the finance literature: stocks with smaller market capitalisation outperform large stocks over the long term. However, a common recommendation in the asset management industry is to remove Size from the factor menu, given its relatively weak post-publication performance. Scientific Beta's analysis differs from recent studies by smart beta providers in assessing the relevance of the Size factor. Rather than asking which factor has the best stand-alone performance, we ask what the marginal impact of the Size factor is when including it in